Aytu BioPharma, Inc. (AYTU) Stock

Aytu BioPharma, Inc. (AYTU) is a Healthcare stock trading at $2.34 (as of 2026-08-21), with a market capitalization of $25.12M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Aytu Biopharma, Inc. develops and commercializes specialty therapeutics and consumer healthcare products in the United States and internationally. Its portfolio includes ADHD treatments (Adzenys XR-ODT, Cotempla XR-ODT, and Adzenys ER) and other therapies such as allergy, antitussive, insomnia, and pediatric supplement products.

Understand Aytu BioPharma, Inc.: how it makes money

Aytu BioPharma develops and commercializes specialty pharmaceutical and consumer healthcare products, selling ADHD therapies such as Adzenys XR-ODT and Adzenys ER, and Cotempla XR-ODT (and other medicines) to patients in the United States and internationally.

Profit is driven by turning ADHD prescription demand into ongoing branded prescriptions dispensed through the companys distribution or network (notably Prescription Connection), since management tracks prescription volume and the dispensed share of branded ADHD prescriptions.

Revenue by segment (latest quarter)
Prescription$0.0B
Consumer$0.0B

Business quality (Weak): Gross margin is positive, but the latest quarter shows a large operating loss, and reported revenue is extremely small, so investors should focus on whether prescription demand and branded dispensed share can translate into sustainable profitability.

Bull case

  • Prescription activity is measurable and sizable: Attention Deficit Hyperactivity Disorder Prescriptions Written were 94,000.
  • Branded ADHD prescriptions show strong network dispensation share: Percent of Branded Attention Deficit Hyperactivity Disorder Prescriptions Dispensed Through Prescription Connection is 85%.

Bear case

  • Latest quarter profitability is weak: Operating margin is -32.7% (gross margin is 61.2%).
  • Revenue is very small in the reported period: Financials show revenue_b of 0.0B for the quarter ended 2026-03-31.
Valuation — source: SEC EDGAR (first-party)
Price$2.34
Market Cap$25.12M
Price / Book0.71
Price / Sales0.42
FCF Yield-14.6%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$66.38M
Net Margin-20.4%
Revenue Growth (YoY)-32.7%
EPS Growth (YoY)-181.5%
FCF Growth (YoY)-76.9%
Financial Health — source: SEC EDGAR
Altman Z-Score-3.15 (distress)
Piotroski F-Score5/9 (moderate)
Valuation vs Sector & Industry
Sector P/E (Healthcare)21.7
Industry P/E (Pharmaceutical Products)17.0
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderArete Wealth Advisors, LLC ($3.99M)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEOJoshua R. Disbrow
Employees102
CountryUS
IPO Date2008-09-25

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • Optimi Health Corp. (OPTH)
  • BioXcel Therapeutics, Inc. (BTAI)
  • Atossa Therapeutics, Inc. (ATOS)
  • Cellectar Biosciences, Inc. (CLRB)
  • TherapeuticsMD, Inc. (TXMD)
  • ABVC BioPharma, Inc. (ABVC)
  • Marker Therapeutics, Inc. (MRKR)
  • Allarity Therapeutics, Inc. (ALLR)
AYTU earnings history · AYTU institutional & insider holders · AYTU KPIs & operating metrics · AYTU financials · AYTU investor presentations & press releases · AYTU SEC filings · AYTU peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-08-21.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.